Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
暂无分享,去创建一个
J. Cerhan | T. Habermann | S. Ansell | H. Tun | T. Witzig | Yucai Wang | G. Nowakowski | D. Inwards | J. Paludo | L. Porrata | A. Rosenthal | A. Tun | A. Matin | J. V. Bisneto | P. B. Johnston | Ivana N. Micallef | P. Johnston
[1] S. Ansell,et al. SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma. , 2021, Clinical lymphoma, myeloma & leukemia.
[2] N. Johnson,et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. , 2021, The Lancet. Oncology.
[3] R. Küppers,et al. Molecular biology of Hodgkin lymphoma , 2021, Leukemia.
[4] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[5] I. Lossos,et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. , 2020, Blood.
[6] J. Serody,et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Advani,et al. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[8] S. Ansell. Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management , 2020, American journal of hematology.
[9] A. Szabo,et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. , 2020, Blood advances.
[10] G. Heinze,et al. An unjustified benefit: immortal time bias in the analysis of time‐dependent events , 2018, Transplant international : official journal of the European Society for Organ Transplantation.
[11] J. Connors,et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma , 2017, The New England journal of medicine.
[12] S. Schuster,et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis , 2017, American journal of hematology.
[13] M. Shipp,et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Raemaekers,et al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Bouabdallah,et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma , 2017, Bone Marrow Transplantation.
[16] K. Savage,et al. Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study , 2016, The Lancet. Oncology.
[17] F. d'Amore,et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. , 2016, The New England journal of medicine.
[18] J. Radford,et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[19] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[20] M. Ravic,et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. , 2011, Blood.
[21] J. Snowden,et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] S. Horning,et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant , 2013, Leukemia & lymphoma.
[23] A. Zelenetz,et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Scott E Smith,et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] V. Diehl,et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Garcia-conde,et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[27] A. Zelenetz,et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma , 2003, Bone Marrow Transplantation.
[28] Dirk Hasenclever,et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.
[29] V. Diehl,et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.